Growth in the first quarter came from a strong underlying sales and earnings performance, but was also the result of a challenged first quarter 2009. The most important currencies have developed favorably since the previous guidance and are now expected to impact the full year positively. Sales are now expected to grow by 6-8% in DKK and by 4-6% in LCY. EBIT is expected to grow by 12-14%, and the EBIT margin is expected at around 21%. Net profit is expected to grow by 17-19%, and free cash flow before acquisitions is expected at DKK 800-900 million. Read the whole company announcement
Strong Q1 performance and increased expectations for full year 2010
| Source: Novonesis (Novozymes A/S)